ABL Bio to Hold Overseas NDR in the United States

ABL Bio, a company specializing in bispecific antibodies, announced on January 6 that it will conduct an overseas Non-Deal Roadshow (NDR) in the United States starting from January 19 (local time).

Through this NDR, ABL Bio plans to meet with overseas institutional investors to introduce its bispecific antibody technology, pipeline development status, and future business strategies. The company aims to use this opportunity to strengthen trust with overseas investors, with whom communication has been limited, and to enhance shareholder value by attracting foreign capital.

ABL Bio is presenting its business around four key areas: ABL001 (Tovecimig), the blood-brain barrier (BBB) shuttle platform Grabody-B, the 4-1BB-based bispecific antibody platform Grabody-T, and next-generation ADCs.

ABL001 (Tovecimig) is a DLL4 and VEGF-A targeted bispecific antibody developed by ABL Bio and out-licensed to the US biotech company Compass Therapeutics. It is currently undergoing Phase 2/3 clinical trials as a second-line treatment for cholangiocarcinoma. Compass Therapeutics plans to announce the full Phase 2/3 clinical data in the first half of this year and submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) based on these results.

Grabody-B is a shuttle technology that targets IGF1R (Insulin-like Growth Factor 1 Receptor) to improve drug delivery efficiency. In April last year, ABL Bio signed a Grabody-B technology transfer agreement with the global pharmaceutical company GSK worth 2.1401 billion pounds (approximately 4.1 trillion won). In November of the same year, the company signed a Grabody technology transfer agreement with Eli Lilly worth 2.602 billion dollars (approximately 3.8 trillion won), along with a strategic equity investment agreement worth 15 million dollars (approximately 22 billion won), drawing significant attention.

Grabody-T is used to develop bispecific antibody immuno-oncology drugs that activate T cells within the tumor microenvironment where cancer cells are expressed. Among the Grabody-T based pipelines, ABL111 (Givastomig) is progressing the fastest and has shown promising results in a Phase 1b clinical trial for patients with metastatic gastric cancer through combination therapy with the PD-1 inhibitor nivolumab and the chemotherapy regimen mFOLFOX6. The company also plans to expand clinical trials for combination therapies with other candidates such as ABL503 (Ragistomig).

Additionally, ABL Bio is developing next-generation ADCs, including bispecific antibody ADCs and dual payload ADCs. Recently, the company submitted an Investigational New Drug (IND) application to the US FDA for a Phase 1 clinical trial of ABL206, a bispecific antibody ADC candidate, and is also preparing an IND for a Phase 1 clinical trial of ABL209.

Lee Sanghoon, CEO of ABL Bio, stated, "As the company's market capitalization has increased following the technology transfer agreements with GSK and Lilly, we have received numerous NDR requests from global asset managers and funds. We intend to use this as an opportunity to attract overseas passive funds and enhance shareholder value. Starting with this US NDR, we are also considering NDRs in major countries such as Hong Kong and Singapore. We will continue to promote our technology and do our utmost to grow into a global biotech company."